CPH
RVNC

C Partners Holding’s Revance Therapeutics, Inc. RVNC Stock Holding History

C Partners Holding’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-24,000
Closed -$407K – 51
2014
Q4 		$407K Buy
+24,000
New +$419K 0.13% 47

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NHG
NQ HCIF GP Raleigh, North Carolina $50.2M AUM 45.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

C Partners Holding's RVNC Position: Q1 2015 in Review

C Partners Holding sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2015, closing a stake of 24,000 shares — an estimated $407K sold.

C Partners Holding first reported a position in RVNC in Q4 2014 and held it in 1 quarter. The position peaked at $407K in Q4 2014. 70 funds tracked by Wall St. Rank hold RVNC as of Q1 2015.

  • C Partners Holding reported no remaining Revance Therapeutics, Inc. position as of Q1 2015 after selling out during the quarter.
  • C Partners Holding sold 24,000 Revance Therapeutics, Inc. shares in Q1 2015, an estimated $407K.
  • C Partners Holding first reported a position in Revance Therapeutics, Inc. in Q4 2014 and held it in 1 quarter.
  • C Partners Holding's Revance Therapeutics, Inc. position peaked at $407K in Q4 2014.
  • 70 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2015.

Based on C Partners Holding's 13F filing for Q1 2015, filed 21 Apr 2015.